Risperidone-Induced Neutropenia in a Schizophrenic Patient: A Case Report and Literature Review.


Journal

Case reports in psychiatry
ISSN: 2090-682X
Titre abrégé: Case Rep Psychiatry
Pays: United States
ID NLM: 101583308

Informations de publication

Date de publication:
2021
Historique:
received: 11 05 2021
accepted: 10 08 2021
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 28 8 2021
Statut: epublish

Résumé

Neutropenia is an adverse effect of various pharmacological therapies, including antipsychotics. Among the second-generation antipsychotic (SGA) medications, clozapine is most notable for neutropenic adverse effect. Risperidone, another SGA drug, is linked mainly with metabolic adverse effects, but rarely, blood dyscrasia adverse reactions have been reported. Hence, we report the case of a 56-year-old African American woman who developed severe neutropenia following two weeks of oral risperidone treatment. Her neutrophil levels returned to normal limits following discontinuation of risperidone and switching to haloperidol.

Identifiants

pubmed: 34447597
doi: 10.1155/2021/3980872
pmc: PMC8384506
doi:

Types de publication

Case Reports

Langues

eng

Pagination

3980872

Informations de copyright

Copyright © 2021 Ayodele Atolagbe et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Ann Hematol. 2020 Nov;99(11):2477-2482
pubmed: 32815018
Neuropsychiatr Dis Treat. 2017 Jul 25;13:1975-1977
pubmed: 28794632
Schizophr Bull. 2009 Sep;35(5):937-48
pubmed: 18400811
Expert Opin Drug Saf. 2003 Jul;2(4):395-9
pubmed: 12904095
J Assoc Physicians India. 2000 Nov;48(11):1122-3
pubmed: 11310398
Eur Neuropsychopharmacol. 1995 Mar;5(1):1-2; discussion 3
pubmed: 7542050
Semin Hematol. 2013 Jul;50(3):198-206
pubmed: 23953336
World Psychiatry. 2015 Jun;14(2):119-36
pubmed: 26043321
Expert Opin Drug Saf. 2020 Aug;19(8):981-998
pubmed: 32657173
Psychiatr Serv. 1996 Jan;47(1):52-6
pubmed: 8925346
J Neuropsychiatry Clin Neurosci. 2011 Fall;23(4):E19
pubmed: 22231329
Int Clin Psychopharmacol. 1996 Mar;11(1):53-4
pubmed: 8732314
Hum Psychopharmacol. 2008 Jan;23 Suppl 1:27-41
pubmed: 18098216
Brain Behav Immun. 2006 Nov;20(6):532-45
pubmed: 16580814
Ther Adv Drug Saf. 2018 May;9(5):237-256
pubmed: 29796248

Auteurs

Ayodele Atolagbe (A)

Department of Psychiatry, Interfaith Medical Center, Brooklyn, NYC, NY, USA.

Stanley Nkemjika (S)

Department of Psychiatry, Interfaith Medical Center, Brooklyn, NYC, NY, USA.
Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA.

Olusegun Popoola (O)

Department of Psychiatry, Interfaith Medical Center, Brooklyn, NYC, NY, USA.

Oluwatoyin Oladeji (O)

Department of Psychiatry, Interfaith Medical Center, Brooklyn, NYC, NY, USA.

Irina Kogan (I)

Department of Psychiatry, Interfaith Medical Center, Brooklyn, NYC, NY, USA.

Haroon Saeed (H)

Department of Psychiatry, Interfaith Medical Center, Brooklyn, NYC, NY, USA.

Tolulope Olupona (T)

Department of Psychiatry, Interfaith Medical Center, Brooklyn, NYC, NY, USA.

Classifications MeSH